CN1057192C - Method for preparing preservation liquid for various kinds of living organs and the prepns. thereof - Google Patents
Method for preparing preservation liquid for various kinds of living organs and the prepns. thereof Download PDFInfo
- Publication number
- CN1057192C CN1057192C CN97106600A CN97106600A CN1057192C CN 1057192 C CN1057192 C CN 1057192C CN 97106600 A CN97106600 A CN 97106600A CN 97106600 A CN97106600 A CN 97106600A CN 1057192 C CN1057192 C CN 1057192C
- Authority
- CN
- China
- Prior art keywords
- add
- clear
- liquid color
- until liquid
- stirring becomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The present invention provides a method for preparing improved multiple-organ preserving liquid, and a product thereof, which is characterized in that the preserving liquid is added with low-molecular dextran-40, sucrose and calcium ion antagonist, original adding components are removed, and the pH value is regulated to be weakly-alkaline. The method of the present invention is easy to control. The multiple-organ preserving liquid prepared and produced by the method of the present invention has the advantages of low cost, good preserving effect and convenient storage, transportation and use, and can satisfy the requirements of the field of organ transplantation, which is increasingly developed. By the success of a low-temperature preserving test for animals, and low-temperature preservation and clinical transplantation for partial organs of a human body, the product of the present invention is the effective multiple-organ preserving liquid.
Description
The present invention relates to the preservation technology of medical domain human body, animal body or its part, is a kind of method and goods thereof of preparing new multi-organ preservation solution.
The China organ transplant General Board Xia Suisheng of association professor points out in " kidney transplant of expectation China obtains some suggestions of the bigger progress " commentary of " Chinese organ transplant magazine " the 15th the 4th phase of volume in October, 1994: " the initiative success of UW liquid (by Univ Wisconsin-Madison USA; University ofWiscosin; a kind of multi-organ preservation solution that professor Belzer etc. succeeded in developing in 1987; be the most successful in the world up to now multi-organ preservation solution; be with historically new significance on the organ transplant history; be called for short UW liquid), prolong the cold holding time of donor organ significantly (can reach 72 hours) for kidney, make preservation liquid enter a new period, extensive use in the world, domestic also have indivedual units to begin to use UW liquid in liver transfer operation, expectation China not only just introduces, but utilize it to preserve principle, the UW type solution of developing the homemade multiple improvement of China comes, and uses to apply." owing to lack and to be similar to UW liquid or to be better than the so long-acting multi-organ preservation solution of UW liquid; in a sense; restriction and obstacle the development of other the big organ transplant work except that kidney transplant, so develop a kind of new multi-organ preservation solution and be significant.
The object of the present invention is to provide a kind of method and goods thereof of preparing new more efficiently multi-organ preservation solution, further reduced cost, increase preservation effect, conveniently store, transport and use, can satisfy the needs of growing organ transplant circle.
The object of the present invention is achieved like this is at first being analyzed on the basis of UW formula of liquid comprehensively meticulously, and in conjunction with the new development of Organ Preservation, is improved.Process for preparation is in distilled water, add lactobionic acid, potassium hydroxide, sodium hydroxide, adenosine, allopurinol, potassium dihydrogen phosphate, magnesium sulfate, sucrose, reduced glutathione, isoptin, dexamethasone, dextran-40 by quantitatively strict and condition order, carry out pH value and capacity adjustment again.There are 5 points in the place of change: 1. substitute HES (E.I.Du Pont Company's specialities) with D-40-40 (molecular weight is 40.000), further to reduce cost, increase preservation effect, especially aspect microcirculation; 2. with cane sugar substitution kapok sugar; 3. remove adding ingredient in the UW liquid, as insulin, heparin, penicillin, Batricn (trimethoprim (TMP)); 4. add calcium ion antagonist-isoptin; 5. the pH value further is adjusted into inclined to one side alkali (7.45 ± 0.10).
The present invention has following advantage and positive effect: a kind of method of preparing new more efficiently multi-organ preservation solution provided by the present invention is easy to grasp, preparation and production that prescription that those of ordinary skill can provide by this method and step are carried out this multi-organ preservation solution.Multi-organ preservation solution with this method preparation and production is a kind of new more efficiently multi-organ preservation solution.Be characterized in: reduced cost, increased preservation effect, made things convenient for storage, transportation and use, can satisfy the needs of growing organ transplant circle.Through animal organ's's (kidney, liver, heart, lungs, pancreas, small intestine etc.) low temperature being preserved experiment and trying out in the low temperature preservation of part human organ and the success of clinical transplantation, confirm a kind of new more efficiently multi-organ preservation solution of the present invention, low temperature preservation effect to kidney, liver, heart, lungs, pancreas, small intestine etc. is analogous to external UW liquid substantially, and partial results is better than UW liquid, approximately can preserve kidney 72 hours, liver 30 hours, heart 18-24 hour, pancreas 48 hours etc.Its usage is: available simple hypothermia perfusion method or consecutive low temperature machine method for filling are preserved each organ.
Below further set forth concrete prescription of the present invention and implementation step.
The inventor recommends following prescription, its composition content (/L) scope is respectively:
1, lactobionic acid (Lactobionate Acid) 99~101mmol
2, potassium dihydrogen phosphate (KH
2PO
4) 24~26mmol
3, magnesium sulfate (MgSO
4) 4~6mmol
4, adenosine (Adenosine) 4~6mmol
5, glutathione reduced form (Glutathione) 2~4mmol
6, dexamethasone (Dexame thasone) 8mg
7, allopurinol (Allopurinol) 0.5~1.5mmol
8, sodium hydroxide 5N (NaOH 50mmol/L) 4~6ml
9, potassium hydroxide 5N (KOH 5mmol/L) 19~21ml
10, sucrose (Sucrose) 50~70mmol
11, dextran-40 (Dextran-40) 40-60g
12, isoptin (Isoptin) 20mg
pH:7.45+0.10:Permeate?pressure:310±10mOsm/L
(osmotic pressure: 310 ± 10mOsm/L)
Concrete steps are as follows:
List process for preparation by the 1000ml amount below:
1. distilled water: the distilled water that in 1 liter container, adds 400ml earlier.It is 20-24 ℃ generally in room temperature.
2. lactobionic acid: add the 35.83g lactobionic acid, stir become until liquid color clear.
3. potassium hydroxide: add 20ml 5N potassium hydroxide, and stirred 5 minutes.
4. sodium hydroxide: add 5.0ml 5N sodium hydroxide, and stirred 5 minutes.
5. adenosine: add adenosine 1.34g, stir become until liquid color clear.
6. allopurinol: add the 0.136g allopurinol, stir become until liquid color clear.
7. potassium dihydrogen phosphate: add the 3.4g potassium dihydrogen phosphate, stir become until liquid color clear.
8. magnesium sulfate: add 0.60g magnesium sulfate, stir become until liquid color clear.
9. sucrose: add 20.538g sucrose, stir become until liquid color clear.
10. glutathione: add the 0.92g glutathione, stir become until liquid color clear.
11. isoptin: add the isoptin of 20ml, it is clear that stirring becomes until liquid color.
12. dexamethasone: add the 8mg dexamethasone, it is clear that stirring becomes until liquid color.
13. dextran-40: add dextran-40 500ml (10%), heat and dissolve.
14.pH the adjusting of value: as conditioning agent, pH is adjusted to 7.45 ± 0.10 with the sodium hydroxide of 5N.
15. capacity adjustment: add distilled water to 1000ml.And stirred 5 minutes.
Above-mentioned process for preparation is all prepared under strict aseptic condition.
This multi-organ preservation solution adopts the aseptic filtration sterilization.
This multi-organ preservation solution needs to store under 0-4 ℃ of temperature.
This multi-organ preservation solution is the 2-3 month the 0-4 ℃ of term of validity.
Prepare the chemical reagent source of this multi-organ preservation solution:
1, lactobionic acid (Lactobionate Acid)
Aldrich?Chemical?Co.,Milwaukee,WI,#15.351-6.97%
FW:358.30 mP113~118℃
[α]D20+25°(C=10,H2,24hrs)
Beil.31,415,Merck?Index?11,5219
NMR?2(1),460B?FT-IR?1(1),5250,Disp.A
2, adenosine (Adenosine)
Sigma?A?9251
C
10H
13N
5O
4
FW:267.2
3, glutathione reduced form (Glutathione.Reduced from)
Sigma?G?4251
C
10H
12N
3O
6S
FW:307.3
4, allopurinol (Allopurinol) 0.5-1.5mmol
Sigma?A?8003
4-Hydroxypyrazolo[3,4-d]-pyrimidine;HPP
C
5H
4N
4O
FW:136.1
5, isoptin (Isoptin)
Verapamil?hydrochloride
composition:
2ml?of?injection?solution?contain?5?mg?of?verapamil?hydrochloride
Knoll?AG.D6700?Ludwigshafen.?Germany
6, sucrose (Sucrose)
Shanghai reagent one factory
C
12H
12O
11
FW:342.30
Specific rotatory power [α] 20/D+66.40~+ 66.60
7, dextran-40 claims glucan (Dextran-40) again
Chemical reagent station, Shanghai packing factory
FW:40.000
8, sodium hydroxide (Sodium Hydroxide)
NaOH
Reagent four factories in Shanghai supervise
FW:40.00
NaOH content is no less than 96.0%
Na
2CO
3Content is not more than 1.5%
9, potassium dihydrogen phosphate (Potassium Phosphate Monobasic)
Shanghai reagent two factories under the chemical reagent head factory of Shanghai
KH
2PO
4
FW:136.09
10, potassium hydroxide (Potassium Hydroxide)
Shanghai development chemical reagent work
KOH
FW:56.10
11, magnesium sulfate (Magnesium Sulfate)
MgSO
4
FW:120.38
12, dexamethasone
Shanghai the 9th pharmaceutical factory
1ml contains 5mg
Claims (1)
1, a kind of method of preparing multi-organ preservation solution is prepared under the aseptic condition of strictness, and adopts aseptic filtration method sterilization, and the concrete steps of pressing 1000ml amount process for preparation are as follows:
20~30 ℃ of of In room temperature is under, adds successively in 1 liter container:the distilled water of 400ml; Add the 35.83g lactobionic acid, it is clear that stirring becomes until liquid color; Add 20ml 5N potassium hydroxide, and stirred 5 minutes; Add 5.0ml 5N sodium hydroxide, and stirred 5 minutes; Add adenosine 1.34g, it is clear stirring until liquid color; Add the 0.136g allopurinol, it is clear that stirring becomes until liquid color; Add the 3.4g potassium dihydrogen phosphate, it is clear that stirring becomes until liquid color; Add 0.60g magnesium sulfate, it is clear that stirring becomes until liquid color; Add 20.538g sucrose, it is clear that stirring becomes until liquid color; Add 0.92g glutathione reduced form, it is clear that stirring becomes until liquid color; The isoptin that adds 20mg, it is clear that stirring becomes until liquid color; Add the 8mg dexamethasone, it is clear that stirring becomes until liquid color; Add dextran-40 500ml (10%), heat and dissolve; As conditioning agent, pH is adjusted to 7.45 ± 0.10 with the sodium hydroxide of 5N; Add distilled water to 1000ml, and stirred 5 minutes; It is characterized in that its composition calculates content range by every liter and is: lactobionic acid 99-101mmol potassium dihydrogen phosphate 24-26mmol magnesium sulfate 4-6mmol adenosine 4-6mmol glutathione reduced form 2-4mmol dexamethasone 8mg allopurinol 0.5-1.5mmol5N NaOH 4-6ml5N potassium hydroxide 19-21ml sucrose 50-70mmol dextran-40 40-60g isoptin 20mg
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97106600A CN1057192C (en) | 1997-09-10 | 1997-09-10 | Method for preparing preservation liquid for various kinds of living organs and the prepns. thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97106600A CN1057192C (en) | 1997-09-10 | 1997-09-10 | Method for preparing preservation liquid for various kinds of living organs and the prepns. thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1176738A CN1176738A (en) | 1998-03-25 |
CN1057192C true CN1057192C (en) | 2000-10-11 |
Family
ID=5168825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97106600A Expired - Fee Related CN1057192C (en) | 1997-09-10 | 1997-09-10 | Method for preparing preservation liquid for various kinds of living organs and the prepns. thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1057192C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100423638C (en) * | 2007-03-22 | 2008-10-08 | 南京吉脉生物技术有限公司 | Organ preserving fluid and its prepn |
US10251905B2 (en) | 2006-05-29 | 2019-04-09 | Hibernation Therapeutics, A Kf Llc | Tissue maintenance |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0010653A (en) | 1999-03-23 | 2002-02-05 | Univ James Cook | Stop, protection and preservation of organs |
GB0028414D0 (en) * | 2000-11-22 | 2001-01-03 | Univ Leeds | Flush preservation solution |
SE525461C3 (en) * | 2002-11-28 | 2005-03-23 | Prophymed Ab | New use of dextran sulfate |
WO2007030198A2 (en) * | 2005-07-11 | 2007-03-15 | Human Biosystems | Improved methods and solutions for storing donor organs |
ES2539762T3 (en) | 2006-07-25 | 2015-07-03 | Hibernation Therapeutics, A Kf Llc | Trauma treatment |
CN100382688C (en) * | 2006-09-29 | 2008-04-23 | 中国人民解放军第三军医大学第一附属医院 | Normal temperature and sub-normal temperature in vitro heart preserving perfusate |
AU2008222595B2 (en) | 2007-03-02 | 2014-03-27 | Hibernation Therapeutics, A Kf Llc | Transplants |
CN101999344B (en) * | 2010-12-27 | 2013-12-18 | 协和干细胞基因工程有限公司 | In-vitro tissue preserving fluid and preparation method thereof |
WO2015006830A1 (en) | 2013-07-17 | 2015-01-22 | Hts Therapeutics Pty Ltd | A method for organ arrest, protection and preservation and reducing tissue injury |
US11246308B2 (en) * | 2016-12-20 | 2022-02-15 | Tissue Testing Technologies Llc | Ice-free preservation of large volume tissue samples for viable, functional tissue banking |
CN108633878B (en) * | 2018-07-11 | 2021-05-04 | 上海理工大学 | Isolated organ protection solution |
CN109221084A (en) * | 2018-09-20 | 2019-01-18 | 中国人民解放军第二军医大学第二附属医院 | A kind of dedicated preservation liquid of pancreas and preparation method thereof |
CN112056307A (en) * | 2020-08-24 | 2020-12-11 | 四川大学华西医院 | Umbilical cord preservation liquid and umbilical cord preservation method |
CN112790189B (en) * | 2021-03-10 | 2022-04-22 | 四川大学华西医院 | Organ perfusion and preservation solution and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5576814A (en) * | 1978-12-06 | 1980-06-10 | Green Cross Corp:The | Preservative solution for organ transplant |
WO1987001940A1 (en) * | 1985-10-03 | 1987-04-09 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
US4920044A (en) * | 1988-11-08 | 1990-04-24 | The Cleveland Clinic Foundation | Intracellular flush solution for preserving organs |
WO1993004578A1 (en) * | 1991-09-12 | 1993-03-18 | Mount Sinai Hospital Corporation | Composition for the preservation of organs |
GB2270614A (en) * | 1992-09-18 | 1994-03-23 | Pasteur Merieux Serums Vacc | Solution for the perfusion, preservation and reperfusion of organs |
-
1997
- 1997-09-10 CN CN97106600A patent/CN1057192C/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5576814A (en) * | 1978-12-06 | 1980-06-10 | Green Cross Corp:The | Preservative solution for organ transplant |
WO1987001940A1 (en) * | 1985-10-03 | 1987-04-09 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
US4920044A (en) * | 1988-11-08 | 1990-04-24 | The Cleveland Clinic Foundation | Intracellular flush solution for preserving organs |
WO1993004578A1 (en) * | 1991-09-12 | 1993-03-18 | Mount Sinai Hospital Corporation | Composition for the preservation of organs |
GB2270614A (en) * | 1992-09-18 | 1994-03-23 | Pasteur Merieux Serums Vacc | Solution for the perfusion, preservation and reperfusion of organs |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10251905B2 (en) | 2006-05-29 | 2019-04-09 | Hibernation Therapeutics, A Kf Llc | Tissue maintenance |
CN100423638C (en) * | 2007-03-22 | 2008-10-08 | 南京吉脉生物技术有限公司 | Organ preserving fluid and its prepn |
Also Published As
Publication number | Publication date |
---|---|
CN1176738A (en) | 1998-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1057192C (en) | Method for preparing preservation liquid for various kinds of living organs and the prepns. thereof | |
CN1914228A (en) | Esters of hyaluronic acid with rhein, process for their preparation and compositions comprising the same | |
MX2007004490A (en) | Compositions containing piperacillin, tazobactam and a aminocarboxilic acid in a sodium lactate diluent. | |
BR112019004449B1 (en) | GLYCOSAMINOGLYCAN, METHOD FOR THE PRODUCTION OF A BIOSYNTHETIC HEPARIN AND METHODS FOR THE PRODUCTION OF SECOND AND THIRD INTERMEDIATES COMPRISING GLYCOSAMINOGLYCAN | |
CN1827109A (en) | Lyophilized injection powder using Lanluodier and its salt as active ingredients and preparing technique therefor | |
CN1739505A (en) | L-ornidazole injection prepn | |
GB2074445A (en) | Oral pharmaceutical compositions containing cytidine diphosphocholine | |
DK167225B1 (en) | PROCEDURE FOR PREPARING A WHOLE SACCHAROMYCES CEREVISIAE CELL CULTURE | |
CN1081932C (en) | Endotoxin stabilizing agent, endotoxin composition and method for assaying endotoxin | |
CN1263736C (en) | Solution of tetrahydrate N-[ortho-(para-trimethyl acetoxyl benzenesulfonamide) benzoyl] glycine monosodium salt and its medicine | |
CN108203723B (en) | Method for producing high-content polymyxin B1 through fermentation | |
CN1041107A (en) | Promote the method for pig growth | |
CN1152964C (en) | Process for protecting enzyme activity in serum used for quality control in clinical chemistry | |
CN101066274A (en) | Prepn process of double salt potassium D-aminogluconate sulfate | |
US7026507B2 (en) | Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate | |
CN1098624A (en) | Be used to prevent crapulent pharmaceutical preparation and preparation method thereof | |
CN1351866A (en) | Levo-potassium magnesium aspartate freeze drying powder injection and preparing method | |
CN1745746A (en) | Hydroxypropyl-beta-cyclodextrin coating material of borneol an dits preparing method | |
CN88101780A (en) | Method of stabilizing proteins | |
Levene et al. | ON THE ACTION OF LEUCOCYTES ON HEXOSES. FOURTH COMMUNICATION. ON THE MECHANISM OF LACTIC ACID FORMATION. | |
CN1628691A (en) | Adenosine triphosphate salt composition and preparation method thereof | |
JPH0795850A (en) | Formulated milk for infant | |
CN1372540A (en) | Non-hydroscopic salts of active ingredients having therapeutical and/or nutritional activities and orally administrable compositions containing same | |
CN1061405A (en) | The title complex that contains S (+)-phenyl alkane acids and Alpha-hydroxy paraffinic acid | |
RU2009146017A (en) | WAYS OF TABLING |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |